애네불로 파마슈티컬스(ANEB)는 NASDAQ에 상장된 Healthcare · Biotechnology 기업입니다. 현재가 $0.32 (+6.67%), 시가총액 $0.02B, 52주 범위 $0.33 ~ $3.33.
Anebulo Pharmaceuticals, Inc., a clinical-stage biotechnology company, engages in developing treatments for unintentional cannabis poisoning, acute cannabinoid intoxication, and acute cannabis-induced conditions in the United States. The company's lead product candidate is the selonabant, a small-molecule antagonist of cannabinoid binding receptor type-1(CB1), which is in a phase II clinical trial to address the unmet medical need for a specific antidote for cannabis toxicity. Anebulo Pharmaceuticals, Inc. was incorporated in 2020 and is headquartered in Lakeway, Texas.
애네불로 파마슈티컬스의 재무제표, 목표주가, 기관투자자(13F) 보유 현황, 관련 뉴스는 BlackQuant에서 실시간으로 확인할 수 있습니다.
애네불로 파마슈티컬스의 현재 주가는 $0.32 (+6.67%)입니다. BlackQuant에서 실시간 시세와 차트를 확인할 수 있습니다.
애네불로 파마슈티컬스의 시가총액은 약 $0.02B입니다.
Anebulo Pharmaceuticals, Inc., a clinical-stage biotechnology company, engages in developing treatments for unintentional cannabis poisoning, acute cannabinoid intoxication, and acute cannabis-induced